热门资讯> 正文
艾伯维完成对Capstan Therapeutics的收购
2025-08-19 22:26
- AbbVie (NYSE:ABBV) has completed its acquisition of clinical-stage biotech Capstan Therapeutics.
- The deal, first announced in late June, is worth up to $2.1B.
- Captan's lead asset, CPTX2309, is a targeted lipid nanoparticle, anti-CD19 CAR-T therapy for B cell-mediated autoimmune diseases in phase 1.
More on AbbVie
- AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition
- AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
- 4 Reasons To Buy AbbVie
- Short bets on S&P 500 Healthcare sector ease in July; Moderna remains most heavily shorted stock
- AbbVie to invest $195M to build plant in Illinois
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
